Contact Information
37 Westminster Buildings, Theatre Square,
Nottingham, NG1 6LG
Bristol Myers Squibb to Acquire Mirati Therapeutics in Deal Worth Up to $5.8 Billion
The deal expands the pharmaceutical company’s portfolio of cancer drugs. Source link
The World Needs New Antibiotics, but the Business Model Is Broken
New drugs to defeat “superbug” bacteria aren’t reaching patients. Source link
Ozempic Settles the Obesity Debate: It's Biology Over Willpower
Weight-loss drugs affect the brain in ways that help researchers understand how the body regulates weight. Source link
Weight-Loss Drug Wegovy Cuts Heart Risk in New Study
Novo Nordisk’s anti-obesity drug reduced people’s risk of suffering heart attacks, strokes and cardiovascular deaths by 20%. Source link
Employers Cut Off Access to Weight-Loss Drugs for Workers
Costs are mounting for popular drugs such as Wegovy, a cousin of Ozempic, and healthcare plans are restricting coverage to save money. Source link
Venture Capitalist Seeks to Spur Drug Development for Rare Autoimmune Disease
Venture capitalist Luke Evnin has financed several successful biotechnology startups that develop treatments for cancer. Now he is encouraging drugmakers to tackle another disease: a rare autoimmune condition that
Hedge Funds Seek to Cut Off $1 Billion Meant for Opioid Victims
Drugmaker Mallinckrodt is talking to hedge funds about filing for bankruptcy and avoiding payments intended to help people addicted to opioids. Source link
Biogen to Cut Roughly 11% of Workforce
The biotech cited the launch of Alzheimer’s drug Leqembi as part of its new focus on big-return products. Source link
Big Pharma Bets Big on China
China remains attractive to global pharmaceutical companies even as many multinationals shift their focus elsewhere. Source link
J&J Revenue Up on Surge in Heart Procedures
Net earnings at the pharmaceutical company rose 6.9% to $5.14 billion, or $1.96 a share. Source link
